Adverse reactions to biologic agents: Focus on autoimmune disease therapies
Authors:
- Arthur KavanaughAKArthur Kavanaugh
- 1 October 2005
- journal article
- review article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 116 (4) , 900-905
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Lymphoma in rheumatoid arthritis: The effect of methotrexate and anti–tumor necrosis factor therapy in 18,572 patientsArthritis & Rheumatism, 2004
- Anti–tumor necrosis factor α therapy and the risk of lymphoma in rheumatoid arthritis: No clear answerArthritis & Rheumatism, 2004
- Targeted Anticytokine Therapy in Patients With Chronic Heart FailureCirculation, 2004
- Infliximab Maintenance Therapy for Fistulizing Crohn's DiseaseNew England Journal of Medicine, 2004
- Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart FailureCirculation, 2003
- Anti-TNF-?-induced systemic lupus syndromeClinical Rheumatology, 2003
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Rituximab-Induced VasculitisDermatology, 2001
- Hapten-Induced Primary and Memory Humoral Responses Are Inhibited by the Infusion of Anti-CD20 Monoclonal Antibody (IDEC-C2B8, Rituximab)Clinical Immunology, 2001
- Prevention and amelioration of collagen‐induced arthritis by blockade of the CD28 co‐stimulatory pathway: requirement for both B7‐1 and B7‐2European Journal of Immunology, 1996